Loading…
Zevra Therapeutics, Inc. is projected to rise to $15.68 by 2027, a +43% move from its current price of $10.95. ZVRA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $10.64 | $10.96 | $11.28 | +0.08% |
| May 30 | $10.52 | $10.97 | $11.43 | +0.16% |
| May 31 | $10.43 | $10.98 | $11.54 | +0.24% |
| Jun 1 | $10.36 | $10.98 | $11.64 | +0.32% |
| Jun 2 | $10.30 | $10.99 | $11.73 | +0.39% |
| Jun 3 | $10.24 | $11.00 | $11.82 | +0.47% |
| Jun 4 | $10.19 | $11.01 | $11.89 | +0.55% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.19 | $11.01 | $11.89 | +0.55% |
| Week 2 | $9.93 | $11.07 | $12.35 | +1.11% |
| Week 3 | $9.74 | $11.13 | $12.72 | +1.67% |
| Week 4 | $9.59 | $11.19 | $13.06 | +2.23% |
| Week 5 | $9.47 | $11.26 | $13.38 | +2.79% |
| Week 6 | $9.37 | $11.32 | $13.67 | +3.36% |
| Week 7 | $9.28 | $11.38 | $13.96 | +3.93% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Zevra Therapeutics, Inc. is a Healthcare company focused on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through its Ligand Activated Technology platform.
Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy.
In addition, Zevra is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. It also offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of Niemann-Pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreements with Commave Therapeutics SA to develop, manufacture and commercialize product candidates containing SDX and d-methylphenidate; and license agreements with Acer and Relief Therapeutics, Inc.
to develop and commercialize rights for OLPRUVA.
The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. It was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Zevra Therapeutics, Inc. (ZVRA) is a healthcare company focused on rare diseases and led by a portfolio of product candidates across multiple indications. The current price is $10.95 with a market capitalization of $647.31M and a market ranking of 2820.
The current price and market position frame a stock that sits near a bullish technical backdrop, supported by a 30-day trading range and ongoing development in its clinical pipeline.
Forecasts show a multi-year path toward higher average prices from 2026 onward, with substantial upside potential reflected in the long-run averages and ROIs. The 2026 average price is $10.95, implying a flat near-term trajectory, with years ahead projecting meaningful growth to $25.22 by 2030 and beyond to $144.53 by 2050, underscoring a bullish longer-term outlook based on the modeled trajectory.
A major floor 23.7% below — a decisive break under it would weaken the trend.
The nearest floor, 11.7% below — buyers have tended to step in here.
The nearest ceiling, 6.5% above — a clean break opens room to run.
A major ceiling 16.4% above — clearing it would confirm fresh momentum.
Key ZVRA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ZVRA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.41 | Buy | $10.54 | Buy |
| MA 10 | $10.64 | Buy | $10.56 | Buy |
| MA 20 | $10.61 | Buy | $10.52 | Buy |
| MA 50 | $10.08 | Buy | $10.17 | Buy |
| MA 100 | $9.52 | Buy | $9.81 | Buy |
| MA 200 | $9.39 | Buy | $9.46 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.02 | Neutral |
| Stoch RSI (14) | 48.51 | Neutral |
| CCI (20) | 50.48 | Neutral |
| Williams %R (14) | -43.56 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -1.62 | Sell |
| Bollinger %B (20,2) | 0.67 | Neutral |
| Stochastic %K (14) | 56.44 | Neutral |
| TRIX (15) | 0.27 | Buy |
| Awesome (5,34) | -0.00 | Sell |
| Ultimate (7,14,28) | 48.87 | Neutral |
| Momentum (10) | -0.10 | Sell |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 10.33 | Buy |
| ADX (14) | 13.06 | Neutral |
| ATR (14) | 0.32 | Info |
The 30-day technical picture is bullish overall. The RSI14 stands at 60, and the stock trades above the SMA50 of $10.08 and above the SMA200 of $9.39, indicating constructive momentum.
Near-term support is cited at $9.67 and resistance at $11.66, with a 30-day range spanning $9.03 to $13.27. This suggests a measured upside path, with the possibility of testing the resistance level if buying interest remains steady in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.31 | $10.95 | $14.37 | 0% | Neutral | |
| $12.36 | $15.68 | $21.14 | +43% | Bullish | |
| $15.42 | $20.16 | $28.21 | +84% | Bullish | |
| $16.70 | $22.37 | $32.26 | +104% | Bullish | |
| $18.43 | $25.22 | $37.30 | +130% | Bullish | |
| $19.25 | $26.88 | $40.63 | +145% | Bullish | |
| $20.82 | $29.62 | $45.68 | +171% | Bullish | |
| $22.98 | $33.27 | $52.23 | +204% | Bullish | |
| $27.10 | $39.89 | $63.66 | +264% | Bullish | |
| $32.49 | $48.61 | $78.78 | +344% | Bullish | |
| $43.83 | $70.54 | $121.89 | +544% | Bullish | |
| $79.11 | $144.53 | $274.24 | +12.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $8.31 | $10.95 | $12.87 | +0.00% |
| June 2026 | $9.63 | $11.33 | $13.66 | +3.49% |
| July 2026 | $9.91 | $11.76 | $14.38 | +3.82% |
| August 2026 | $9.65 | $11.53 | $14.25 | -1.99% |
| September 2026 | $9.40 | $11.31 | $14.10 | -1.95% |
| October 2026 | $9.58 | $11.58 | $14.56 | +2.43% |
| November 2026 | $9.56 | $11.60 | $14.69 | +0.20% |
| December 2026 | $9.24 | $11.28 | $14.37 | -2.83% |
Click any year to see its month-by-month ZVRA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Zevra Therapeutics, Inc.'s 2026 outlook centres on $10.95, within a $8.31 to $14.37 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ZVRA could reach as high as $21.14, with a base case around $15.68 and support toward $12.36 — roughly +43% from $10.95. Buyers look set to stay in control over this stretch.
Expect ZVRA to range from $15.42 to $28.21 through 2028. The $20.16 average target implies a +84% move from current prices. That is up +29% on the projected 2027 average. Momentum favours further upside here.
The ZVRA price prediction for 2029 points to an average of $22.37 (low $16.70, high $32.26) — a potential gain of +104% on today's $10.95. Buyers look set to stay in control over this stretch.
In 2030, ZVRA is projected to trade between $18.43 and $37.30, averaging $25.22 — a potential gain of +130% from today's $10.95. That is up +13% on the projected 2029 average. Momentum favours further upside here.
Zevra Therapeutics, Inc.'s 2031 outlook centres on $26.88, within a $19.25 to $40.63 range. That is up +7% on the projected 2030 average. That marks a +145% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ZVRA could reach as high as $45.68, with a base case around $29.62 and support toward $20.82 — roughly +171% from $10.95. Momentum favours further upside here.
Expect ZVRA to range from $22.98 to $52.23 through 2033. The $33.27 average target implies a +204% move from current prices. That is up +12% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ZVRA price prediction for 2034 points to an average of $39.89 (low $27.10, high $63.66) — a potential gain of +264% on today's $10.95. Momentum favours further upside here.
In 2035, ZVRA is projected to trade between $32.49 and $78.78, averaging $48.61 — a potential gain of +344% from today's $10.95. That is up +22% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Zevra Therapeutics, Inc.'s 2040 outlook centres on $70.54, within a $43.83 to $121.89 range. That is up +45% on the projected 2035 average. That marks a +544% change versus current levels. Momentum favours further upside here.
By 2050, ZVRA could reach as high as $274.24, with a base case around $144.53 and support toward $79.11 — roughly +12.2x from $10.95. Buyers look set to stay in control over this stretch.
Investing $1,000 in ZVRA today (≈ 91.324201 ZVRA) could be worth
$13,198.9
+$12,198.9 (+1220%) by 2050 · US Dollar
Based on the average projected ZVRA price of $144.53 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ZVRAwould be worth at today's price.
$1,000 invested in ZVRA on May 27, 2025 (≈ 118.343198 ZVRA) would be worth
$1,295.86
+$295.86 (+29.6%) today · 1.30× · US Dollar
Based on a ZVRA entry price of $8.45 vs. today's $10.95.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.24 | $1,069.34 | +6.9% |
| 1 month ago | $9.81 | $1,116.21 | +11.6% |
| 3 months ago | $9.09 | $1,204.62 | +20.5% |
| 6 months ago | $8.43 | $1,298.93 | +29.9% |
| 1 year ago | $8.45 | $1,295.86 | +29.6% |
| All time (5.0y) ago | $10.87 | $1,007.36 | +0.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ZVRA forecast.
Our base-case forecast reaches $22.00 around 2029.
Implied market cap at $22.00: $1.3B
In the multi-year forecast, Zevra’s average price rises from $10.95 in 2026 to $25.22 in 2030 and then to $144.53 by 2050, with increasingly higher max prices over time. The 2026 forecast shows a min of $8.31, an avg of $10.95, and a max of $14.37, with a 0 ROI, and a neutral sentiment. By 2027 the avg climbs to $15.68 with a max of $21.14 and a 43.2 ROI, and the sentiment turns bullish.
The trajectory continues higher through 2028 ($20.16 avg, $28.21 max, 84.1 ROI), 2029 ($22.37 avg, $32.26 max, 104.3 ROI), 2030 ($25.22 avg, $37.30 max, 130.3 ROI), 2031 ($26.88 avg, $40.63 max, 145.5 ROI), 2032 ($29.62 avg, $45.68 max, 170.5 ROI), 2033 ($33.27 avg, $52.23 max, 203.8 ROI), 2034 ($39.89 avg, $63.66 max, 264.3 ROI), 2035 ($48.61 avg, $78.78 max, 343.9 ROI), 2040 ($70.54 avg, $121.89 max, 544.2 ROI), and 2050 ($144.53 avg, $274.24 max, 1219.9 ROI). The long-term outlook is bullish across the forecast horizon, but these are estimates and not guarantees. Investors should consider the inherent uncertainty and the fact that outcomes depend on a range of factors including clinical progress and regulatory developments.
Tap a question to reveal the answer.
The forecast for 2030 shows a min of $18.43, an avg of $25.22, and a max of $37.30, with a 130.3 ROI and a bullish sentiment.
Short-term sentiment is bullish in the forecast and technical picture. The 30-day range is $9.03 to $13.27, the RSI14 is 60, and the stock sits above the SMA50 ($10.08) and SMA200 ($9.39), with support at $9.67 and resistance at $11.66.
Yes, the 2050 forecast max is $274.24, with an average of $144.53, indicating the potential to exceed $200 in the longer term. Earlier years show lower maximums, e.g., 2040 max $121.89.
Current price: $10.95. Market cap: $647.31M.
For 2026, the min is $8.31, the avg is $10.95, the max is $14.37, with a 0 ROI and neutral sentiment.
Zevra Therapeutics, Inc. Community Discussion
0Share your Zevra Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.